Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis

Eur Respir J. 2019 Jul 25;54(1):1802208. doi: 10.1183/13993003.02208-2018. Print 2019 Jul.

Authors

Irina Vasilyeva¹, Andrei Mariandyshev², Boris Kazennyy³, Edita Davidavičienė⁴, Nacer Lounis⁵, Sofia Keim⁶; on behalf of the TMC207TBC3001 study group

Affiliations

¹ National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russia [email protected].
² Dept of Tuberculosis, Northern State Medical University, Arkhangelsk, Russia.
³ Orel Oblast Tuberculosis Dispensary, Orel, Russia.
⁴ National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania.
⁵ Janssen Pharmaceutica NV, Beerse, Belgium.
⁶ Janssen-Cilag, Porto Salvo, Portugal.

PMID: 31097518
DOI: 10.1183/13993003.02208-2018

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antitubercular Agents / therapeutic use*
Diarylquinolines / therapeutic use*
Extensively Drug-Resistant Tuberculosis / drug therapy*
Female
Humans
Male
Middle Aged
Treatment Outcome
Tuberculosis, Multidrug-Resistant / drug therapy
Young Adult

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline